A1 Journal article – refereed
Quality of life after endovascular sclerotherapy of low-flow venous malformations: the efficacy of polidocanol compared with ethanol

List of Authors: Annamaria Weitz-Tuoretmaa, Leo Keski-Nisula, Riitta Rautio, Jussi Laranne
Publisher: Sage
Publication year: 2018
Journal: Acta Radiologica
Volume number: 59
Issue number: 8
eISSN: 1600-0455


Background: Limited information is available on mid-term results and quality of life (QOL) after endovascular sclerotherapy of venous malformations.

Purpose: To compare two agents—polidocanol and ethanol—with a focus on the influence on QOL after sclerotherapy.

Material and Methods: Forty-one consecutive patients with a venous malformation in the head and neck area or in the extremities were treated with polidocanol between 2008 and 2013. Pre- and post-treatment magnetic resonance imaging (MRI) scans were compared. All patients completed a self-evaluation form on symptoms as well as a QOL questionnaire. The results were compared with previously obtained material during 1991–2001, comprising 44 consecutive, similarly located venous malformation patients subject to ethanol sclerotherapy.

Results: No significant clinical complications were observed. Subjectively, 19 (46%) of the patients benefitted from the treatment. QOL results showed that 85% of patients had an index < 39 – where 0 represents the highest and 100 the lowest QOL. Patients in the ethanol group had marginally better overall post-treatment QOL results. Post-treatment MRI in 35 patients showed the size of the malformation unchanged in 19 (54%) patients, in ten (29%) there was a decrease (<50%) while in six (17%) the decrease was more significant (>50%). Post-treatment MRI results did not correlate with either subjective symptoms or QOL results.

Conclusion: Polidocanol sclerotherapy were found to be an effective, safe, and well tolerated treatment option for low flow venous malformations. Routine MRI for follow-up appears redundant and may be omitted.

Last updated on 2019-29-01 at 18:17